AbbVie, Teva Hit With 2 More Niaspan Pay-For-Delay Suits
By Scott Flaherty ( May 1, 2013, 1:36 PM EDT) -- AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were hit Tuesday with a pair of putative antitrust class actions challenging a pay-for-delay deal that allegedly harmed consumers by keeping a generic version of AbbVie's cholesterol drug Niaspan off the market....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.